342 related articles for article (PubMed ID: 16323253)
1. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease.
Takeda A; Loveman E; Clegg A; Kirby J; Picot J; Payne E; Green C
Int J Geriatr Psychiatry; 2006 Jan; 21(1):17-28. PubMed ID: 16323253
[TBL] [Abstract][Full Text] [Related]
2. Cholinesterase inhibitors for Alzheimer's disease.
Birks J
Cochrane Database Syst Rev; 2006 Jan; 2006(1):CD005593. PubMed ID: 16437532
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.
Hansen RA; Gartlehner G; Webb AP; Morgan LC; Moore CG; Jonas DE
Clin Interv Aging; 2008; 3(2):211-25. PubMed ID: 18686744
[TBL] [Abstract][Full Text] [Related]
4. Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials.
Atri A; Frölich L; Ballard C; Tariot PN; Molinuevo JL; Boneva N; Windfeld K; Raket LL; Cummings JL
JAMA; 2018 Jan; 319(2):130-142. PubMed ID: 29318278
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of treated patients with Alzheimer's disease: current trends and COVID-19 impact.
Olazarán J; Carnero-Pardo C; Fortea J; Sánchez-Juan P; García-Ribas G; Viñuela F; Martínez-Lage P; Boada M
Alzheimers Res Ther; 2023 Aug; 15(1):130. PubMed ID: 37537656
[TBL] [Abstract][Full Text] [Related]
6. Clinical trials in mild cognitive impairment: lessons for the future.
Jelic V; Kivipelto M; Winblad B
J Neurol Neurosurg Psychiatry; 2006 Apr; 77(4):429-38. PubMed ID: 16306154
[TBL] [Abstract][Full Text] [Related]
7. Psychiatric Adverse Events of Acetylcholinesterase Inhibitors in Alzheimer's Disease and Parkinson's Dementia: Systematic Review and Meta-Analysis.
Bittner N; Funk CSM; Schmidt A; Bermpohl F; Brandl EJ; Algharably EEA; Kreutz R; Riemer TG
Drugs Aging; 2023 Nov; 40(11):953-964. PubMed ID: 37682445
[TBL] [Abstract][Full Text] [Related]
8. Cholinesterase inhibitors for delirium.
Overshott R; Karim S; Burns A
Cochrane Database Syst Rev; 2008 Jan; 2008(1):CD005317. PubMed ID: 18254077
[TBL] [Abstract][Full Text] [Related]
9. Effects of Acetylcholinesterase Inhibitors on Nutritional Status in Elderly Patients with Dementia: A 6-month Follow-up Study.
Soysal P; Isik AT
J Nutr Health Aging; 2016 Apr; 20(4):398-403. PubMed ID: 26999239
[TBL] [Abstract][Full Text] [Related]
10. Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease.
Aisen PS; Cummings J; Schneider LS
Cold Spring Harb Perspect Med; 2012 Mar; 2(3):a006395. PubMed ID: 22393531
[TBL] [Abstract][Full Text] [Related]
11. Adverse Effects of Cholinesterase Inhibitors in Dementia, According to the Pharmacovigilance Databases of the United-States and Canada.
Ali TB; Schleret TR; Reilly BM; Chen WY; Abagyan R
PLoS One; 2015; 10(12):e0144337. PubMed ID: 26642212
[TBL] [Abstract][Full Text] [Related]
12. Butyrylcholinesterase inhibitors ameliorate cognitive dysfunction induced by amyloid-β peptide in mice.
Furukawa-Hibi Y; Alkam T; Nitta A; Matsuyama A; Mizoguchi H; Suzuki K; Moussaoui S; Yu QS; Greig NH; Nagai T; Yamada K
Behav Brain Res; 2011 Nov; 225(1):222-9. PubMed ID: 21820013
[TBL] [Abstract][Full Text] [Related]
13. Effect of long-term treatment with galantamine on weight of patients with Alzheimer's dementia.
Droogsma E; van Asselt DZ; van Steijn JH; Schuur T; Huinink EJ
J Nutr Health Aging; 2013; 17(5):461-5. PubMed ID: 23636548
[TBL] [Abstract][Full Text] [Related]
14. Donepezil for Alzheimer's disease: pharmacodynamic, pharmacokinetic, and clinical profiles.
Shigeta M; Homma A
CNS Drug Rev; 2001; 7(4):353-68. PubMed ID: 11830754
[TBL] [Abstract][Full Text] [Related]
15. Consumption of drugs for Alzheimer's disease on the Brazilian private market.
Freitas EL; Calil-Elias S; Erbisti RS; Grinberg-Weller B; Miranda ES
Rev Saude Publica; 2023; 57():83. PubMed ID: 37971177
[TBL] [Abstract][Full Text] [Related]
16. Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease.
Lilienfeld S
CNS Drug Rev; 2002; 8(2):159-76. PubMed ID: 12177686
[TBL] [Abstract][Full Text] [Related]
17. A combination of galantamine and memantine modifies cognitive function in subjects with amnestic MCI.
Peters O; Lorenz D; Fesche A; Schmidtke K; Hüll M; Perneczky R; Rüther E; Möller HJ; Jessen F; Maier W; Kornhuber J; Jahn H; Luckhaus C; Gertz HJ; Schröder J; Pantel J; Teipel S; Wellek S; Frölich L; Heuser I
J Nutr Health Aging; 2012; 16(6):544-8. PubMed ID: 22659994
[TBL] [Abstract][Full Text] [Related]
18. Evaluating the efficacy and safety of Alzheimer's disease drugs: A meta-analysis and systematic review.
Chen Y; Lai M; Tao M
Medicine (Baltimore); 2024 Apr; 103(16):e37799. PubMed ID: 38640313
[TBL] [Abstract][Full Text] [Related]
19. Cholinesterase inhibitors and falls, syncope and injuries in patients with cognitive impairment: a systematic review and meta-analysis.
Ahuja M; Siddhpuria S; Karimi A; Lewis K; Wong E; Lee J; Reppas-Rindlisbacher C; Sood E; Gabor C; Patterson C
Age Ageing; 2023 Nov; 52(11):. PubMed ID: 37993407
[TBL] [Abstract][Full Text] [Related]
20. Current Treatment Options for Alzheimer's Disease and Parkinson's Disease Dementia.
Szeto JY; Lewis SJ
Curr Neuropharmacol; 2016; 14(4):326-38. PubMed ID: 26644155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
